Lisata Therapeutics Files 8-K

Ticker: LSTA · Form: 8-K · Filed: Oct 14, 2025 · CIK: 320017

Sentiment: neutral

Topics: 8-K, disclosure, financials

Related Tickers: CLBS

TL;DR

Lisata Therapeutics filed an 8-K on 10/14/25 with Reg FD disclosures and financial exhibits.

AI Summary

Lisata Therapeutics, Inc. filed an 8-K on October 14, 2025, reporting on a Regulation FD Disclosure and Financial Statements and Exhibits. The company, formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc., is incorporated in Delaware and operates in the Pharmaceutical Preparations sector. Its principal executive offices are located in Basking Ridge, NJ.

Why It Matters

This filing provides an update on the company's regulatory disclosures and financial exhibits, which are crucial for investors to assess its current standing and future prospects.

Risk Assessment

Risk Level: low — This is a routine filing of an 8-K, primarily containing disclosures and exhibits, rather than a material event like a merger or significant financial change.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing?

The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.

What is the current name of the registrant?

The current name of the registrant is LISATA THERAPEUTICS, INC.

What were some of the previous names of the company?

The company was formerly known as CALADRIUS BIOSCIENCES, INC. and NeoStem, Inc.

Where are the principal executive offices of Lisata Therapeutics, Inc. located?

The principal executive offices are located at 110 Allen Road, Second Floor, Basking Ridge, NJ 07920.

On what date was this 8-K report filed?

This 8-K report was filed on October 14, 2025.

Filing Stats: 520 words · 2 min read · ~2 pages · Grade level 10.2 · Accepted 2025-10-14 16:02:38

Key Financial Figures

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 14, 2025, Lisata Therapeutics, Inc. (the "Company") issued a slide presentation that the Company will use at investor and industry conferences and presentations. A copy of this presentation is attached to this Current Report as Exhibit 99.1 and is incorporated herein solely for purposes of this Item 7.01 disclosure. The information in this Item 7.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information in this Item 7.01, including Exhibit 99.1 attached hereto, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act of 1933, except as otherwise expressly stated in such filing.

01. Financial Statement and Exhibits

Item 9.01. Financial Statement and Exhibits. Exhibit No. Description 99.1 Lisata Therapeutics, Inc. Corporate Presentation, October 14, 2025

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. LISATA THERAPEUTICS, INC. By: /s/ David J. Mazzo Name: David J. Mazzo, PhD Title: President & Chief Executive Officer Dated: October 14, 2025

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing